Mecasermin rinfabate is under clinical development by Chiesi Farmaceutici and currently in Phase II for Bronchopulmonary Dysplasia. According to GlobalData, Phase II drugs for Bronchopulmonary Dysplasia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Mecasermin rinfabate LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mecasermin rinfabate overview
Mecasermin rinfabate (Iplex) is a recombinant human biologic protein complex of insulin-like growth factor-1 (IGF-1). It is formulated as injectable solution for subcutaneous route of administration. It is indicated in the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD).
Mecasermin rinfabate (Iplex) is under development for treatment of chronic respiratory morbidity (CRM) including bronchopulmonary dysplasia (BPD). It was also under development for the treatment of burns, myotonic dystrophy, Rabson–Mendenhall syndrome, Leprechaunism, retinopathy of prematurity and severe intraventricular hemorrhage, Laron syndrome, type A and type B extreme insulin resistance syndrome.
Chiesi Farmaceutici overview
Chiesi Farmaceutici (Chiesi) researches, develops, produces and commercializes novel medicines with a focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, ankylosing spondylitis, hypertension, percutaneous coronary intervention, apnoea of prematurity, respiratory distress syndrome, lipoprotein lipase deficiency (LPLD), limbal stem cell deficiency (LSCD) and inflammatory bowel diseases, among others. The company operates production sites in Parma, Italy; Blois, France; and Santana De Parnaiba, Brazil; and conducts research and development activities in its R&D center in Parma and at laboratories in Paris (France), Chippenham (the UK), Cary (the US) and Lidingo (Sweden). Chiesi is headquartered in Parma, Emilia-Romagna, Italy.
For a complete picture of Mecasermin rinfabate’s drug-specific PTSR and LoA scores, buy the report here.